Study supports cell saver autotransfusion in dogs and cats
Bottom line
A retrospective study in Veterinary Surgery evaluated perioperative autotransfusion with a cell saver device in 103 small animal cases, including 102 dogs and one cat, spanning both emergency and elective procedures. According to the study abstract, the technique was safe and effective, with a transfusion reaction rate of 1%, and it offered a viable alternative to allogeneic blood products. That adds one of the larger case series yet to the veterinary literature on cell salvage, a technique already described as feasible in dogs and increasingly used in small animal practice when major blood loss is expected. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary teams managing hemoabdomen, complex soft tissue surgery, thoracic procedures, or other cases with substantial blood loss risk, the findings support cell salvage as a practical blood conservation strategy. That matters in a field where donor blood can be limited, expensive, or not immediately available, and where transfusion still requires close monitoring for hemolytic, febrile, allergic, and circulatory complications. Prior veterinary reports have also found cell saver use to be safe and effective in dogs, including a 2025 study in dogs with acute hemoperitoneum that found no adverse effect on time to surgery, surgical duration, or outcome. (merckvetmanual.com)
What to watch: Watch for the full paper’s publication details, including case mix, indications, device protocol, and whether the authors identify which patients are most likely to benefit from perioperative autotransfusion. (onlinelibrary.wiley.com)
Key facts
- Study type
- Retrospective study
- Journal
- Veterinary Surgery
- Sample size
- 103 small animal cases
- Species
- 102 dogs and one cat
- Setting
- Emergency and elective procedures
- Intervention
- Perioperative autotransfusion using a cell saver device
- Key finding
- Safe and effective
- Transfusion reaction rate
- 1%
- Conclusion
- Viable alternative to allogeneic blood products
A new retrospective study in Veterinary Surgery reports that perioperative autotransfusion using a cell saver device was safe and effective in 102 dogs and one cat undergoing emergency and elective procedures. In the abstract, the authors report a transfusion reaction rate of 1% and conclude that the approach provides a viable alternative to allogeneic blood products. (pubmed.ncbi.nlm.nih.gov)
The report lands amid growing veterinary interest in patient blood management and alternatives to donor blood, especially for surgical patients at risk of major hemorrhage. Cell salvage has been used in human medicine for decades, and veterinary literature has gradually expanded from technical descriptions and small case series toward broader clinical outcome studies. An earlier review in Journal of Veterinary Emergency and Critical Care described automated blood salvage devices as a feasible option in dogs, with the potential to reduce reliance on banked blood and avoid some morbidities associated with allogeneic and stored products. (pubmed.ncbi.nlm.nih.gov)
More recently, a 2025 retrospective study of 43 dogs with acute hemoperitoneum of splenic origin found that autotransfusion collected with a cell saver device appeared safe and effective, and did not adversely affect time from presentation to surgery, surgery duration, or outcomes. Another 2024 report from a referral hospital examined the impact of introducing a cell salvage device on canine surgical transfusions, underscoring how the technology is moving from niche rescue use toward more routine integration in referral practice. (pubmed.ncbi.nlm.nih.gov)
In the newly indexed Veterinary Surgery study, the headline numbers stand out because of the case volume: 103 total patients across emergency and elective settings. Based on the available abstract, the main takeaway is straightforward: perioperative cell salvage produced a low reaction rate and functioned as an alternative to donor blood products. The abstract does not, at least in the material publicly available so far, spell out all inclusion criteria, procedure types, transfusion volumes, or detailed adverse event definitions, so those details will matter once the full article is broadly accessible. (pubmed.ncbi.nlm.nih.gov)
Expert-facing background supports why clinicians are paying attention. Merck’s veterinary transfusion guidance notes that blood transfusions require dedicated administration protocols and careful monitoring, and that recipients should be watched closely for fever, hemolysis, respiratory distress, allergic reactions, and infection. Consensus guidance from the Association of Veterinary Hematology and Transfusion Medicine has likewise emphasized prevention, monitoring, diagnosis, and treatment of transfusion reactions. In that context, any strategy that safely reduces exposure to allogeneic blood is clinically meaningful. (merckvetmanual.com)
There are also practical drivers. Veterinary commentary has noted that donor blood is not always readily available and can be cost-prohibitive, particularly in emergency settings or hospitals without robust blood bank infrastructure. Cell salvage is not a fit for every case, and teams still need equipment, protocols, and training, but it can offer another option when blood loss is substantial and compatible products are limited. (veterinarypracticenews.com)
Why it matters: For surgeons, anesthesiologists, emergency clinicians, and transfusion-minded generalists, this study strengthens the evidence base for intraoperative and perioperative autotransfusion in small animal practice. A 1% reaction rate in a 103-patient series is reassuring, especially because veterinary transfusion decisions often happen under time pressure, financial constraints, or limited blood availability. The study may also help practices frame conversations with pet parents around blood planning before high-risk procedures, including whether autologous salvage could reduce dependence on donor products. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step is the full paper, which should clarify patient selection, procedure categories, anticoagulation and washing protocols, reinfusion thresholds, and how the single feline case compares with the canine cohort. More comparative work will also be worth watching, particularly studies that measure whether cell saver use consistently lowers allogeneic transfusion exposure, costs, or complications across different surgical populations. (pubmed.ncbi.nlm.nih.gov)